BOARD OF DIRECTORS
MARK L. BAUM
Melt Pharmaceuticals, Chairman of the Board, Founder and Chief Executive Officer Harrow Health, Inc.
Mr. Mark L. Baum is an accomplished entrepreneur who founded Melt Pharmaceuticals, and has similarly founded multiple pharmaceutical companies over the last decade, including Harrow Health and its subsidiary ImprimisRx, the nation’s leading ophthalmology pharmaceutical compounding business. Mr. Baum’s interest in drug pricing and accessibility advocacy has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on national media networks. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ for the San Diego region life sciences category. Earlier in his career, Mr. Baum started YesRx, an online pharmacy business serving HIV-positive Californians, followed by 10 years of managing capital as a principal investor. Mr. Baum is a graduate of The University of Texas at Arlington and California Western School of Law.
LARRY DILLAHA, M.D.
Chief Executive Officer, Melt Pharmaceuticals
Dr. Larry Dillaha is an experienced executive with 20 years of experience in the pharmaceutical industry. Prior to joining Melt Pharmaceuticals as Chief Executive Officer in June 2021, he served as the Chief Medical Officer of Harrow Health, where he managed the clinical development of all Harrow drug candidates throughout its portfolio of businesses. Previously, he served as Chief Executive Officer of both Repros Therapeutics and CavtheRx, an inception stage biotechnology company, as well as Chief Operating Officer and Chief Medical Officer for other specialty pharmaceutical companies. Dr. Dillaha has served as the senior leader on numerous FDA-approved 505(b)(2) development programs across a broad range of therapeutic areas, generating more than $1 billion in revenues. Dr. Dillaha earned an M.D. degree from the University of Tennessee, Memphis.
JOHN BERDAHL, M.D.
Vance Thompson Vision
Dr. John Berdahl is a board-certified ophthalmologist who specializes in advanced cataract surgery, corneal surgery, and glaucoma surgery at Vance Thompson Vision. Having performed more than 25,000 eye surgeries around the globe, Dr. Berdahl is regarded as one of the leading international cataract surgeons. Dr. Berdahl has been involved in numerous FDA monitored clinical trials assessing innovative technologies in ophthalmology and has published extensive research in the fields of glaucoma and cataract surgery. He also founded Equinox, which focuses on the treatment of glaucoma and other progressive eye diseases, as well as several online resources for surgeons and patients. Dr. Berdahl was recognized by the American Medical Association as the Top Young Physician in South Dakota and was also identified as one of the Top 40 Under 40 Ophthalmologists worldwide. Dr. Berdahl earned his M.D. degree from the Mayo Medical School before completing his residency training at Duke University.
Mr. Andy Corley is an established leader and entrepreneur in the eye-care industry. Notably, he introduced private pay procedures to the eye-care space, which have had a prominent role in the growth of ophthalmology. Mr. Corley co-founded Eyeonics to develop and market the crystalens intraocular lens for the treatment of cataracts. As CEO, he worked to invent and pioneer the “premium channel” for cataract surgery–creating over $10 billion in value for the industry and granting patients choice and control on upgraded healthcare decisions. Eyeonics was sold to Bausch and Lomb, where he served as President of the surgical division until forming Yelroc Consulting. Most recently, Mr. Corley co-founded Flying-L Partners, which invests in and develops innovative technology in the ophthalmic sector, and he currently serves on the board of several eye-care startup companies. Mr. Corley holds a Bachelor of Business Administration degree from Georgia Southern University.